WATERTOWN, Mass., March 30, 2017 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that its pipeline candidate TP-6076 was selected to receive $4 million in research funding from the Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), an international, public-private partnership focused on the discovery and development of new antimicrobial products to address the threat of antibiotic resistance. In preclinical research, TP-6076 has demonstrated potent activity against MDR bacteria, particularly those considered to be urgent or serious threats by the U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO).
“The selection of TP-6076 as one of the first candidates in the CARB-X portfolio highlights the potential of this early stage antibiotic compound due to its exceptional in vitro potency against two of the most dangerous organisms, carbapenem-resistant Enterobacteriaceae (CRE) and carbapenem-resistant Acinetobacter baumannii (CRAB),” said Guy Macdonald, President and CEO of Tetraphase. “This collaboration provides important non-dilutive funding dedicated to the advancement of TP-6076, which recently completed a phase 1 single-ascending dose clinical trial and for which we plan to report data in June at the American Society for Microbiology (ASM) and Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 2017 joint annual meeting.”
CARB-X was launched in July 2016 and represents the world’s largest public-private funding initiative to accelerate the research and development of novel drugs, diagnostics and vaccines to protect human health from the most serious bacterial threats. Companies with early stage projects were selected through a rigorous application process identifying programs that target one of the deadly antibiotic-resistant bacteria on the Serious or Urgent Threat List prepared by the CDC or on the Priority Pathogens list published by the WHO.
About TP-6076
TP-6076 is a novel, synthetic, fluorocycline antibiotic candidate generated through Tetraphase’s proprietary chemistry technology. It has demonstrated potent in vitro activity against multidrug-resistant bacteria including carbapenem-resistant Enterobacteriaceae and carbapenem-resistant Acinetobacter baumannii. As part of an ongoing phase 1 clinical development program, Tetraphase has evaluated intravenous TP-6076 in a phase 1 single-ascending dose clinical trial and is planning to initiate a phase 1 multiple-ascending dose clinical trial in 2017.
About CARB-X
CARB-X is the world’s largest public-private partnership devoted to antibacterial preclinical R&D. Funded by BARDA and Wellcome Trust, with in-kind support from NIAID, we will spend $450 million from 2017-2021 to support innovative products moving towards human clinical trials. CARB-X focuses on high priority drug-resistant bacteria, especially Gram-negatives. CARB-X is a charitable global public-private partnership led by Boston University School of Law. Other partners include the Broad Institute of Harvard and MIT, MassBio, the California Life Sciences Institute and RTI International. For more information, please visit www.carb-x.org and follow us on Twitter @CARB_X.
About Tetraphase Pharmaceuticals, Inc.
Tetraphase is a clinical-stage biopharmaceutical company using its proprietary chemistry technology to create novel antibiotics for serious and life-threatening bacterial infections, including those caused by many of the multidrug-resistant (MDR) bacteria highlighted as urgent public health threats by the CDC. Tetraphase has created more than 3,000 novel tetracycline analogs using its proprietary technology platform. Tetraphase's pipeline includes three antibiotic clinical candidates: eravacycline, which is in phase 3 clinical trials, and TP-271 and TP-6076, which are in phase 1 clinical trials. Please visit www.tphase.com for more company information.
Forward-Looking Statements
Any statements in this press release about our future expectations, plans and prospects, including statements regarding our strategy, future operations, prospects, plans and objectives, and other statements containing the words "anticipates," "believes," "expects," "plans," "will" and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: whether results obtained in previous clinical trials will be indicative of results obtained in future clinical trials; whether any clinical candidate will advance through the clinical trial process on a timely basis or at all; whether the results of the Company's development efforts will warrant regulatory submission and whether any such submissions will receive approval from the United States Food and Drug Administration or equivalent foreign regulatory agencies; whether, if any clinical candidate obtains approval, it will be successfully distributed and marketed; and other factors discussed in the "Risk Factors" section of our quarterly report on Form 10-K, filed with the Securities and Exchange Commission on March 13, 2017. In addition, the forward-looking statements included in this press release represent our views as of March 30, 2017. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so.